ArticleSleep & breathing = Schlaf & Atmung2015
Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome.
Article in Sleep & breathing = Schlaf & Atmung, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- The effects of Desflurane and Sevoflurane on Nesfatin-1 levels in laparoscopic Cholecystectomy: a randomized controlled trial.BMC anesthesiology · 2018Trial
- The Effect of Bioactive Aliment Compounds and Micronutrients on Non-Alcoholic Fatty Liver Disease.Antioxidants (Basel, Switzerland) · 2023Review
- The Modulation of Adipokines, Adipomyokines, and Sleep Disorders on Carcinogenesis.Journal of clinical medicine · 2023Review
- Time-dependence and comparison of regional and overall anthropometric features between Asian and Caucasian populations with obstructive sleep apnea: a cumulative meta-analysis.Journal of thoracic disease · 2021Article
- Obstructive sleep apnoea and cardiovascular disease: a literature review.Archives of medical science : AMS · 2021Article
- Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome.The Eurasian journal of medicine · 2019Review
- Does nesfatin-1 influence the hypothalamic-pituitary-gonadal axis in adult males with obstructive sleep apnoea?Scientific reports · 2019Article
- Nesfatin-1 suppresses peripheral arterial remodeling without elevating blood pressure in mice.Endocrine connections · 2019Article
- Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial.Nutrition & metabolism · 2019Article
- Nesfatin-1 protects dopaminergic neurons against MPPScientific reports · 2017Article
- Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level.Endocrine · 2016Review
- The evaluation of Nesfatin-1 levels in patients with OSAS associated with metabolic syndrome.Journal of endocrinological investigation · 2015Article
- Inflammation in sleep apnea: an update.Reviews in endocrine & metabolic disorders · 2015Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRecent evidences suggest that inflammation is involved in the mechanism of obstructive sleep apnea syndrome (OSAS). Nesfatin-1, recently identified as the satiety regulator, is implicated to possess an anti-inflammatory effect. The aim of our study is to investigate whether serum levels of nesfatin-1 are associated with the presence and severity of OSAS.
methodsA total of 196 patients with OSAS and 104 healthy subjects were enrolled in this study. Serum levels of nesfatin-1 were measured by enzyme-linked immunosorbent assay.
resultsOSAS patients showed significantly reduced levels of serum nesfatin-1 levels than healthy controls. Multivariable logistic regression analysis indicates that serum nesfatin-1 levels were inversely associated with the presence of OSAS (odds ration (OR) 0.003, 95% confidence interval (CI) 0.001 to 0.017; P < 0.001). Serum levels of nesfatin-1 were significantly decreased in severe OSAS patients compared with mild and moderate OSAS patients. Spearman correlation analysis showed that serum nesfatin-1 levels were inversely correlated with the severity of OSAS. In addition, Spearman correlation analysis showed that serum nesfatin-1 levels were negatively correlated with body mass index (BMI) (r = -0.299, P < 0.001), waist-hip ratio (WHR) (r = -0.277, P < 0.001), homeostasis model assessment of insulin resistance (HOMA-IR) (r = -0.338, P < 0.001), and apnea-hypopnea index (AHI) (r = -0.248, P < 0.001) in patients with OSAS.
conclusionsDecreased serum nesfatin-1 levels are associated with the presence and severity of OSAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.